Literature DB >> 27293391

Periostin in the Cancer Stroma of Mycosis Fungoides Palmaris et Plantaris: A Case Report and Immunohistochemical Study.

Kayo Tanita1, Taku Fujimura1, Aya Kakizaki1, Sadanori Furudate1, Masato Mizuashi1, Akiko Watabe1, Setsuya Aiba1.   

Abstract

Mycosis fungoides palmaris et plantaris (MFPP) is a rare variant of mycosis fungoides limited to the palms and soles. Although little is known about the pathogenesis of MFPP, this variant of mycosis fungoides presents a relatively good prognosis. In this report, we describe an 85-year-old Japanese man with MFPP. Immunohistochemical staining revealed the dense deposition of periostin in the cancer stroma, as well as infiltration of CD163(+)CD206(-) tumor-associated macrophages (TAMs), which suggested the phenotypes of TAMs were not polarized to the M2 phenotype in the lesional skin of MFPP. Our present case might suggest one of the possible reasons for the good prognosis of MFPP.

Entities:  

Keywords:  M2 polarization; Mycosis fungoides palmaris et plantaris; Periostin; Prognosis; Tumor-associated macrophages

Year:  2016        PMID: 27293391      PMCID: PMC4899656          DOI: 10.1159/000444162

Source DB:  PubMed          Journal:  Case Rep Dermatol        ISSN: 1662-6567


Introduction

Mycosis fungoides palmaris et plantaris (MFPP) is an uncommon variant of mycosis fungoides (MF) limited to the palms and soles, first described by Resnik et al. in 1995 [1]. Since only 10 English papers about MFPP have been previously published [2], little is known about its pathogenesis. In this report, we describe a case of MFPP showing a dense deposition of periostin (POSTN) in the cancer stroma, which might modulate the tumor microenvi ronment through tumor-associated macrophages (TAMs) [3]. Our present case might suggest one of the possible reasons for the good prognosis of MFPP.

Case Report

An 85-year-old Japanese man visited our outpatient clinic with a 2-year history of pruritic erythema on his scalp. His condition had been treated in a private clinic as pustulosis palmaris et plantaris with topical steroid and maxacalcitol, but they were ineffective. On his initial visit, physical examination revealed erosive, atrophic, well-demarcated scaly erythema on his right palm and right sole (fig. 1a, b). A biopsy specimen showed atypical large lymphocytes densely infiltrated mainly in the upper dermis with involvement of the overlying epidermis (fig. 2a). The epidermotropic lymphocytes formed Pautrier's microabscesses. Immunohistochemical (IHC) staining revealed that these atypical lymphocytes, which were distributed from the upper layer of the stratum spinosum to the dermis, were positive for CD3, CD4 and CD5, and negative for CD7 and CD8. A full blood count and biochemical profile revealed eosinophilia (19.7%), and a significantly high level of serum IL-2 receptor (925 U/ml). We screened for possible metastatic lesions with positron emission tomography and computed tomography but found no evidence of metastasis. From the above findings, we diagnosed this patient as having MFPP. We administered radiation therapy 40 Gy in 20 fractions to the right palm and sole, and the erosive, atrophic erythema then disappeared.
Fig. 1

Erosive, atrophic, well-demarcated scaly erythema with on the patient's right palm (a) and right sole (b).

Fig. 2

Atypical large lymphocytes densely infiltrated mainly in the upper dermis with involvement of the overlying epidermis (a). Paraffin-embedded tissue samples were deparaffinized and stained with anti-POSTN (b), anti-CD163 (c) and anti-CD206 antibodies (d). The sections were developed with liquid permanent red. Original magnification: a ×200, b–d ×100.

To further investigate the possible immunological background of the MFPP, we employed IHC staining for POSTN, CD163 and CD206. IHC staining revealed the dense deposition of POSTN within the superficial to deep dermis (fig. 2b), where CD163+ macrophages were densely infiltrated (fig. 2c). Few CD206+ cells were detected in the lesional skin of the dermis (fig. 2d).

Discussion

MFPP is a rare variant of MF limited to the palms and soles [2, 4, 5]. Since only a small number of cases have been reported in English, the pathogenesis and biological behaviors of MFPP are still incompletely understood [2]. Among the published reports, Nakai et al. [2] reviewed 24 cases of MFPP, which suggested that patients with MFPP present a relatively good prognosis, and that radiotherapy is one of the best therapies for MPFF [2]. Excimer laser therapy (308 nm) and bexarotene are also effective [4, 5] and, to our knowledge, no patients have died from disease progression [2]. POSTN is an extracellular matrix protein that modulates the production of a series of chemokines from macrophages and fibroblasts [3, 6]. As we previously reported, the deposition of POSTN is prominent in early stage (patch to plaque stage) of conventional MF [3]. In addition, previous reports also suggested that in vitro stimulation of monocyte-derived macrophages by POSTN induces the production of chemokines such as CXCL5 and CXCL10 [3], which correlates with the tumor-formation of MF in the early stage [7]. In another report, Zhou et al. [8] reported that POSTN secreted from glioblastoma stem cells increases the M2 TAMs in the tumor site, resulting in the growth of glioblastoma multiformes. These reports suggest that the POSTN/TAM axis might contribute to the progression of the early stage of MF. In our present case, unlike conventional MF in the tumor stage [3], the dense infiltration of atypical lymphoid cells as well as dense deposition of POSTN were observed throughout the dermis. In addition, the main population of TAMs was CD163+CD206– macrophages, which suggested that TAMs were not polarized to M2 macrophages in MFPP. As a previous reports suggested, M2 macrophages produce CCL17 and CCL22 [9, 10, 11], which recruit regulatory T cells (Tregs) in the tumor microenvironment [10]. Since a large population of Tregs is associated with a poor prognosis in various types of human cancer [12], and the depletion of M2-like TAMs delays the cutaneous T-cell lymphoma development in vivo [7], the inhibition of M2 polarization in TAMs might be connected with the progression of MF. Concerning our present case, the phenotypes of TAMs were not polarized to the M2 phenotype, which might be responsible for the good prognosis in MFPP. Since this report presented a single case of MFPP, and since we did not directly prove the relationships between immunomodulatory effects of POSTN and prognosis of MFPP, further analysis of the mechanisms underlying this phenomenon may provide fundamental insights into the mechanisms of POSTN with MFPP. Such clarifications will need to be addressed in future investigations.

Statement of Ethics

The patient gave written informed consent.

Disclosure Statement

The authors declare no conflicts of interest.
  12 in total

1.  Excimer laser therapy (308 nm) for mycosis fungoides palmaris et plantaris: a skin-directed and anatomically feasible treatment.

Authors:  S P Jin; Y K Jeon; K H Cho; J H Chung
Journal:  Br J Dermatol       Date:  2010-09       Impact factor: 9.302

2.  Receptor Activator of NF-κB Ligand Promotes the Production of CCL17 from RANK+ M2 Macrophages.

Authors:  Taku Fujimura; Yumi Kambayashi; Sadanori Furudate; Masayuki Asano; Aya Kakizaki; Setsuya Aiba
Journal:  J Invest Dermatol       Date:  2015-06-08       Impact factor: 8.551

3.  Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis.

Authors:  Masaru Uchida; Hiroshi Shiraishi; Shoichiro Ohta; Kazuhiko Arima; Kazuto Taniguchi; Shoichi Suzuki; Masaki Okamoto; Shawn K Ahlfeld; Koichi Ohshima; Seiya Kato; Shuji Toda; Hironori Sagara; Hisamichi Aizawa; Tomoaki Hoshino; Simon J Conway; Shinichiro Hayashi; Kenji Izuhara
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-12       Impact factor: 6.914

Review 4.  Regulatory T cells in cancer immunotherapy.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2014-01-14       Impact factor: 7.486

5.  Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.

Authors:  Xuesong Wu; Brian C Schulte; Youwen Zhou; Dipica Haribhai; Alexander C Mackinnon; Jose A Plaza; Calvin B Williams; Sam T Hwang
Journal:  J Invest Dermatol       Date:  2014-04-29       Impact factor: 8.551

Review 6.  Mycosis fungoides palmaris et plantaris successfully treated with radiotherapy: case report and mini-review of the published work.

Authors:  Noriaki Nakai; Asami Hagura; Shiho Yamazato; Norito Katoh
Journal:  J Dermatol       Date:  2014-01       Impact factor: 4.005

7.  Mycosis fungoides palmaris et plantaris.

Authors:  K S Resnik; G R Kantor; S R Lessin; M E Kadin; L Chooback; H S Cooper; E C Vonderheid
Journal:  Arch Dermatol       Date:  1995-09

8.  The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides.

Authors:  Sadanori Furudate; Taku Fujimura; Aya Kakizaki; Yumi Kambayashi; Masayuki Asano; Akiko Watabe; Setsuya Aiba
Journal:  Exp Dermatol       Date:  2015-11-23       Impact factor: 3.960

9.  Immunomodulatory effect of bisphosphonate risedronate sodium on CD163+ arginase 1+ M2 macrophages: the development of a possible supportive therapy for angiosarcoma.

Authors:  Taku Fujimura; Yumi Kambayashi; Sadanori Furudate; Aya Kakizaki; Setsuya Aiba
Journal:  Clin Dev Immunol       Date:  2013-12-09

10.  Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.

Authors:  Wenchao Zhou; Susan Q Ke; Zhi Huang; William Flavahan; Xiaoguang Fang; Jeremy Paul; Ling Wu; Andrew E Sloan; Roger E McLendon; Xiaoxia Li; Jeremy N Rich; Shideng Bao
Journal:  Nat Cell Biol       Date:  2015-01-12       Impact factor: 28.824

View more
  1 in total

1.  Mycosis Fungoides Palmaris et Plantaris on the Plantar Aspect of the Foot: A Case Report.

Authors:  Ian Beiser; Joon Yim; Erin Robles-Sherman; Gene S Mirkin; Xingpei Hao
Journal:  Am J Case Rep       Date:  2020-09-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.